Search

Your search keyword '"Girard, N."' showing total 531 results

Search Constraints

Start Over You searched for: Author "Girard, N." Remove constraint Author: "Girard, N." Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
531 results on '"Girard, N."'

Search Results

1. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

2. Assessment of the current and emerging criteria for the histopathological classification of lung neuroendocrine tumours in the lungNENomics project

4. Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R

7. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

14. Les tumeurs thymiques : principes de prise en charge

15. Caractéristiques cliniques et séquences thérapeutiques des patients atteints de cancer bronchique non à petites cellules (CBNPC) métastatique avec mutation KRAS G12C traités par sotorasib dans l’ATUc

16. Caractéristiques et prise en charge des patients porteurs de mutations complexes de l’EGFR dans les cancers bronchiques non à petites cellules : étude multicentrique rétrospective

17. Traitement des cancers bronchiques à petites cellules (CBPC) : intérêt des études en vie réelle. À propos de 2 études de l’IFCT : IFCT-1905 Clinatezo et IFCT-2105 Lurbiclin

18. 115TiP MDT-BRIDGE: A phase II study of neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery and adjuvant D or chemoradiotherapy (CRT) and consolidation D in patients (pts) with resectable or borderline resectable stage IIB–IIIB NSCLC

20. 70P LIST (Lung Initiative on Sequence Therapy): A real-world study of nivolumab for advanced NSCLC in France - First effectiveness, safety, and IO-rechallenge results

21. MA08.04 Assessment of the Quality of the Surgical Procedure and the Operative Report Based on Nationwide French Registry: A RYTHMIC study

22. OA17.03 Real-World Outcomes with Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutated NSCLC (PACIFIC-R)

23. P2.09-29 Efficacy of Osimertinib (OSI) vs 1st-Generation TKI Followed by OSI by Clinical Profile in EGFR-Mutant NSCLC (SMILE STUDY)

25. P1.28-09 Definition of Resectable Stage III Non-small Cell Lung Cancer (NSCLC): A Clinical Case Review by a Pan-European Expert Panel

26. VP4-2023: Sotorasib 960 mg versus 240 mg in pretreated KRAS G12C advanced NSCLC

28. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

35. 84O Neoadjuvant nivolumab (N) + platinum-doublet chemotherapy (C) for resectable NSCLC: 3-y update from CheckMate 816

36. 190P EORTC-SPECTA Arcagen project: Results of the prospective rare thoracic tumors cohort

37. 27P Amivantamab versus alternative real-world anti-cancer therapies in patients with advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations in the US and Europe

38. Cáncer de endometrio: diagnóstico, estudio preterapéutico, tratamiento y seguimiento

39. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer

41. Premières données de vraie vie des patients (pts) atteints d’un cancer bronchique non à petites cellules métastatique (CBNPCm) muté KRAS au sein du programme français d’autorisation temporaire d’utilisation (ATU) : caractéristiques cliniques de 679 pts à l’initiation du traitement

42. Nivolumab (NIVO) + doublet de chimiothérapie à base de sels de platine (chimio) versus chimio, en traitement néoadjuvant du cancer bronchique non à petites cellules (CBNPC) résécable (IB-IIIA) : corrélation entre survie sans évènement (EFS) et régression pathologique dans l’étude CheckMate 816

45. 58O Real-world overall survival (OS) with durvalumab (D) after chemoradiotherapy (CRT) in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC): Interim analysis from the PACIFIC-R study

46. CO73 Amivantamab Versus Real-World Clinical Practice in Europe and the US for Patients With Advanced Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

47. 398TiP MARIPOSA-2: Randomized phase III study of amivantamab + lazertinib + chemotherapy vs chemotherapy alone in EGFR-mutant NSCLC after osimertinib failure

48. Comment effectuer des comparaisons indirectes ajustées par appariement (MAIC) avec imputations multiples des données manquantes et dans un contexte de faibles échantillons ? Une méthodologie illustrée dans le cancer du poumon à partir d'essais cliniques agrégés et de la cohorte nationale ESME-AMLC

49. LBA8 Nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722

Catalog

Books, media, physical & digital resources